Loading ...
Sorry, an error occurred while loading the content.

Zadaxin available in Mexico

Expand Messages
  • HepatitisCinAZ@aol.com
    SciClone Pharmaceuticals Launches Zadaxin(R) in Mexico SAN MATEO, Calif., Aug. 2 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that
    Message 1 of 1 , Aug 2, 2000
    • 0 Attachment
      SciClone Pharmaceuticals Launches Zadaxin(R) in Mexico

      SAN MATEO, Calif., Aug. 2 /PRNewswire/ --
      SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that it has begun
      marketing and distributing ZADAXIN(R), its lead immunotherapy, in Mexico.
      ZADAXIN is also approved for sale in other Latin American markets, including
      Argentina, Venezuela and Peru.
      ZADAXIN marketing and distribution in Latin America is managed for
      SciClone by Craig Olson, a 19-year veteran of Schering-Plough Corporation's
      Latin American business. Olson, who is based in Panama, was recently hired by
      SciClone as Regional Managing Director, Latin America.
      "Mexico represents our first North American product launch and a key to
      the Latin American market as a whole," said Donald R. Sellers, SciClone's
      President and Chief Executive Officer. "Introducing ZADAXIN into this market
      will provide support for our continuing revenue growth and enable key
      audiences in the U.S. to observe the safety and efficacy of ZADAXIN."
      ZADAXIN is approved for sale in 20 countries, principally for the
      treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for
      patients with weakened immune systems.

      SciClone plans to start a phase 3 ZADAXIN hepatitis C program in the U.S. by
      the end of the year.

      The U.S. program will be complemented by a phase 3 hepatitis C program in
      Europe to be conducted by Sigma-Tau S.p.A., SciClone's partner. ZADAXIN is
      in phase 2
      development in the U.S. in combination with lamivudine for the treatment of
      hepatitis B. SciClone plans to initiate U.S. phase 2 ZADAXIN clinical
      programs in liver cancer and malignant melanoma by the end of the year. A
      phase 3 ZADAXIN hepatitis B study is ongoing in Japan. ZADAXIN has been
      administered to over 3,000 subjects in over 70 clinical trials covering a
      broad range of diseases, and an estimated 7,000 patients commercially, with
      virtually no serious drug related side effects or toxicities.
      SciClone Pharmaceuticals is a global specialty pharmaceutical company that
      develops and commercializes novel medicines for the treatment of a broad range
      of the world's most serious diseases. The Company is currently targeting
      malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV,
      drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate
      information from SciClone Pharmaceuticals are available on the Internet at
      www.sciclone.com or by calling the Company's Investor Relations Department at
      800-724-2566. SciClone's Common Stock is listed on The Nasdaq National
      Market(R) under the symbol SCLN.
      The information in this press release includes certain forward-looking
      statements concerning the Company's current expectations regarding future
      events, including continuing ZADAXIN revenue growth, the commercial success of
      ZADAXIN in Latin America, particularly in Mexico, and the ongoing and
      prospective development and commercialization of ZADAXIN immunotherapy in the
      U.S., Europe and Japan for cancer, hepatitis B and hepatitis C, the timing of
      the start and potential for success of the Company's U.S. phase 2 studies for
      cancer and its ZADAXIN phase 3 studies for hepatitis C in the U.S., and
      Sigma-Tau's ZADAXIN phase 3 studies for hepatitis C in Europe. Due to market
      factors and the nature of product development and the regulatory approval
      process, the forward-looking statements contained in this press release are
      subject to risks and uncertainties, including those reflected in the Company's
      filings with the Securities and Exchange Commission, particularly the
      Company's Annual Report on Form 10-K for the year ended December 31, 1999.

      SOURCE SciClone Pharmaceuticals
      -0- 08/02/2000
      /CONTACT: Ruth Koh, Investor Relations of SciClone Pharmaceuticals,
      650-358-3437; or Ian McConnell, Ph.D. of Noonan Russo Communications, Inc.,
      415-677-4455, for SciClone Pharmaceuticals/
      /Web site: http://www.sciclone.com/
      (SCLN)

      SAN MATEO, Calif., Aug. 2 /PRNewswire/ --
      SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that it has begun
      marketing and distributing ZADAXIN(R), its lead immunotherapy, in Mexico.
      ZADAXIN is also approved for sale in other Latin American markets, including
      Argentina, Venezuela and Peru.
      ZADAXIN marketing and distribution in Latin America is managed for
      SciClone by Craig Olson, a 19-year veteran of Schering-Plough Corporation's
      Latin American business. Olson, who is based in Panama, was recently hired by
      SciClone as Regional Managing Director, Latin America.
      "Mexico represents our first North American product launch and a key to
      the Latin American market as a whole," said Donald R. Sellers, SciClone's
      President and Chief Executive Officer. "Introducing ZADAXIN into this market
      will provide support for our continuing revenue growth and enable key
      audiences in the U.S. to observe the safety and efficacy of ZADAXIN."
      ZADAXIN is approved for sale in 20 countries, principally for the
      treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for
      patients with weakened immune systems. SciClone plans to start a phase 3
      ZADAXIN hepatitis C program in the U.S. by the end of the year. The U.S.
      program will be complemented by a phase 3 hepatitis C program in Europe to be
      conducted by Sigma-Tau S.p.A., SciClone's partner. ZADAXIN is in phase 2
      development in the U.S. in combination with lamivudine for the treatment of
      hepatitis B. SciClone plans to initiate U.S. phase 2 ZADAXIN clinical
      programs in liver cancer and malignant melanoma by the end of the year. A
      phase 3 ZADAXIN hepatitis B study is ongoing in Japan. ZADAXIN has been
      administered to over 3,000 subjects in over 70 clinical trials covering a
      broad range of diseases, and an estimated 7,000 patients commercially, with
      virtually no serious drug related side effects or toxicities.
      SciClone Pharmaceuticals is a global specialty pharmaceutical company that
      develops and commercializes novel medicines for the treatment of a broad range
      of the world's most serious diseases. The Company is currently targeting
      malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV,
      drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate
      information from SciClone Pharmaceuticals are available on the Internet at
      www.sciclone.com or by calling the Company's Investor Relations Department at
      800-724-2566. SciClone's Common Stock is listed on The Nasdaq National
      Market(R) under the symbol SCLN.
      The information in this press release includes certain forward-looking
      statements concerning the Company's current expectations regarding future
      events, including continuing ZADAXIN revenue growth, the commercial success of
      ZADAXIN in Latin America, particularly in Mexico, and the ongoing and
      prospective development and commercialization of ZADAXIN immunotherapy in the
      U.S., Europe and Japan for cancer, hepatitis B and hepatitis C, the timing of
      the start and potential for success of the Company's U.S. phase 2 studies for
      cancer and its ZADAXIN phase 3 studies for hepatitis C in the U.S., and
      Sigma-Tau's ZADAXIN phase 3 studies for hepatitis C in Europe. Due to market
      factors and the nature of product development and the regulatory approval
      process, the forward-looking statements contained in this press release are
      subject to risks and uncertainties, including those reflected in the Company's
      filings with the Securities and Exchange Commission, particularly the
      Company's Annual Report on Form 10-K for the year ended December 31, 1999.

      SOURCE SciClone Pharmaceuticals
      -0- 08/02/2000
      /CONTACT: Ruth Koh, Investor Relations of SciClone Pharmaceuticals,
      650-358-3437; or Ian McConnell, Ph.D. of Noonan Russo Communications, Inc.,
      415-677-4455, for SciClone Pharmaceuticals/
      /Web site: http://www.sciclone.com/
      (SCLN)


      Sharon Nicholson

      Hepatitis Education & Patient Coalition (H. E. P. C. in AZ)
      Executive Director

      <A HREF="http://www.suite101.com/welcome.cfm/hepatitis_abc">Hepatitis A, B,
      C's - Editor</A>
      http://www.suite101.com/welcome.cfm/hepatitis_abc

      Are you in ARIZONA?
      Then Join our e-group mailing list online!
      <A HREF="http://www.egroups.com/group/ArizonaHepatitisC">eGroups :
      ArizonaHepatitisC</A>
      http://www.egroups.com/group/ArizonaHepatitisC
    Your message has been successfully submitted and would be delivered to recipients shortly.